---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000112"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T17:31:07.594114+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals appoints Carmine Stengone to Board of Directors

## Summary
- Carmine Stengone (President & CEO of Pipeline Therapeutics) appointed as independent Class I director; term to 2025 annual meeting.
- Stengone raised >$180M and executed a >$1B collaboration with Janssen; expertise in small molecules and neurodegenerative diseases.
- He will advise on strategic decisions and clinical development, notably for KIO-301 (retinitis pigmentosa candidate in ABACUS trial).
- Board determined independence under Nasdaq rules; compensation same as other non-employee directors.
- No arrangements, family relationships, or material transactions with the company since start of last fiscal year.

## SEC filing metadata
- accession: 0001372514-23-000112
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000112/0001372514-23-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000112/kprx-20230801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000112
- JSON: https://secwatch.observer/filing/0001372514-23-000112.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000112.txt

## Key facts
- Executive change
  Carmine Stengone was appointed as Director at KIORA PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Director
  source text: On August 1, 2023, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed Carmine Stengone as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000112/0001372514-23-000112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.